Immunostimulatory oligonucleotides and use thereof in pharmaceuticals
US8592566B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | May 31, 2007 |
| Grant date | Nov 26, 2013 |
| Priority date | — |
| Expiry date | Jul 19, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55561
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A novel immunostimulatory oligonucleotide by which an IFN-inducing activity is enhanced and an inflammatory cytokine-inducing activity is reduced, and a pharmaceutical containing the same, and an application thereof are provided. That is, the present invention provides the immunostimulatory oligonucleotide composed of a base sequence represented by a formula: 5′-(G)MPXCGYQ(G)N-3′ (SEQ ID NO: 118) (X and Y are mutually independent and represent an arbitrary sequence which has a length of 0 to 10 nucleotides and does not contain 4 or more consecutive G residues, and a length of X+Y is 6 to 20 nucleotides; XCGY contains a palindrome sequence having a length of at least 8 nucleotides and has a length of 8 to 22 nucleotides; P and Q are mutually independent and represent one nucleotide other than G; M represents an integer of 6 to 10 and N represents an integer of 0 to 3) wherein a full length thereof is 16 to 37 nucleotides (except for an oligonucleotide composed of a base sequence represented by SEQ ID NO:5), the pharmaceutical application thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.